EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review

Noha A Kamel, Michael A Stokes, Daniel F B Wright, Kamal Sud, Surjit Tarafdar, Ronald L Castelino, Sophie L Stocker

Journal of Nephrology · 2025

DOI: 10.1007/s40620-025-02269-7 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Journal of Nephrology, 2025. Verfasst von Noha A Kamel und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, A15 Pharmacy and Bank Building, Science Road, Camperdown, NSW, 2006, Au…. Hauptthemen laut MEDLINE: Allopurinol, Gout, Gout Suppressants, Renal Dialysis. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Sydney.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urate and oxypurinol, allopurinol’s active metabolite, are predominantly eliminated by the kidneys. Therefore, optimising allopurinol dosing in patients on dialysis is challenging. This review explores allopurinol dosing practices, oxypurinol pharmacokinetics, and effectiveness in gout patients receiving haemodialysis or peritoneal dialysis (PD). Five databases and grey literature were searched. Studies on gout patients on allopurinol, receiving dialysis, and reporting dosing, pharmacokinetics, or effectiveness (reduction in urate and/or gout flares) were included. Abstract, full text screening and data extraction were done by two authors. Studies were grouped by dialysis modality. Eighteen studies were identified including 390 patients, most ( n = 274, 70%) on haemodialysis with allopurinol administered after dialysis. The peritoneal dialytic clearance of oxypurinol (3.14 mL/min, n = 5) and urate (2.7–4 mL/min, n = 25) was similar. The haemodialytic clearance was 78–137 mL/min for oxypurinol ( n = 21) and 80–165 mL/min for urate ( n = 19). Allopurinol doses were higher in haemodialysis (100–600 mg/day) than PD (110–125 mg/day). Haemodialysis sessions decreased oxypurinol and urate concentrations by 39–57% ( n = 30) and 56–71% ( n = 6), respectively. Over time (1–230 days), urate concentrations in haemodialysis ( n = 85) reduced by 14–41%. Target serum urate (< 0.36 mmol/L) was achieved in 61% (20/33) and 47% (13/28) of haemodialysis and PD patients, respectively. Gout flares decreased from 2 to 0.1 attacks/year in patients receiving dialysis ( n = 79). Oxypurinol and urate clearance by haemodialysis was higher than PD, necessitating higher doses of allopurinol. POST dialysis allopurinol doses titrated to target urate are suggested. Future studies considering the impact of dialysis modality on allopurinol dose requirements are needed. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AllopurinolGoutGout SuppressantsRenal DialysisHumansUric AcidTreatment OutcomePeritoneal Dialysis

Stichwörter der Autor:innen

AllopurinolDialysisGoutPharmacokineticsUrate

Substanzen

AllopurinolGout SuppressantsUric Acid

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, A15 Pharmacy and Bank Building, Science Road, Camperdown, NSW, 2006, Australia.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
  • Paediatric Intensive Care Unit, Department of Pharmacy, The Children's Hospital at Westmead, Sydney, NSW, 2031, Australia.
  • Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, NSW, 2010, Australia.
  • Faculty of Medicine, Vincent's Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
  • Nepean Clinical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Förderung

  • University of Sydney

Zitieren

APA

Kamel, N. A., Stokes, M. A., Wright, D. F. B., Sud, K., Tarafdar, S., Castelino, R. L., & Stocker, S. L. (2025). Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review. Journal of Nephrology. https://doi.org/10.1007/s40620-025-02269-7

Vancouver

Kamel NA, Stokes MA, Wright DFB, Sud K, Tarafdar S, Castelino RL, et al. Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review. Journal of Nephrology. 2025. doi:10.1007/s40620-025-02269-7

BibTeX
@article{Kamel2025,
  author = {Kamel, Noha A and Stokes, Michael A and Wright, Daniel F B and Sud, Kamal and Tarafdar, Surjit and Castelino, Ronald L and Stocker, Sophie L},
  title = {Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review},
  journal = {Journal of Nephrology},
  year = {2025},
  doi = {10.1007/s40620-025-02269-7}
}
Kostenlos starten →